Ligand Pharmaceuticals (LGND) Raw Materials (2023 - 2024)
Ligand Pharmaceuticals (LGND) posted Raw Materials of $603000.0 for Q4 2024, down 75.83% sequentially from $2.5 million in Q3 2024, and up 43.57% YoY from $420000.0 in Q1 2024.
Ligand Pharmaceuticals (LGND) Raw Materials (2023 - 2024) Analysis & Trends
Ligand Pharmaceuticals has reported Raw Materials for 2 years, with the latest figure at $603000.0 in Q4 2024.
- Quarterly Raw Materials rose 43.57% year-over-year to $603000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $603000.0 (up 43.57% YoY) and the FY2024 annual result came in at $603000.0, up 43.57% from the prior year.
- Raw Materials declined to $603000.0 in Q4 2024 per LGND's latest filing, from $2.5 million in the prior quarter.
- Over five years, Raw Materials peaked at $2.5 million in Q3 2024 and troughed at $420000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 603,000.00 |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Dec 31, 2023 | 420,000.00 |